1. Home
  2. TTRX vs GNLX Comparison

TTRX vs GNLX Comparison

Compare TTRX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.42

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.69

Market Cap

124.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTRX
GNLX
Founded
2015
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.0M
124.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
TTRX
GNLX
Price
$3.42
$2.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$8.00
$19.75
AVG Volume (30 Days)
17.3K
187.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.10
EPS
N/A
N/A
Revenue
N/A
$8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$1.99
52 Week High
$5.98
$8.54

Technical Indicators

Market Signals
Indicator
TTRX
GNLX
Relative Strength Index (RSI) 42.29 44.98
Support Level $2.64 $2.31
Resistance Level $5.12 $2.80
Average True Range (ATR) 0.23 0.17
MACD 0.02 0.05
Stochastic Oscillator 29.58 39.83

Price Performance

Historical Comparison
TTRX
GNLX

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: